Journal of Viral Hepatitis最新文献

{"title":"Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties","authors":"Christopher J. Gonzalez,&nbsp;Clarence N. Perez-Mejia,&nbsp;Noelia Hernandez,&nbsp;Shashi N. Kapadia,&nbsp;Jeff Niederdeppe,&nbsp;Arpan Dharia,&nbsp;Zoi Papalamprakopoulou,&nbsp;Andrew H. Talal,&nbsp;Audrey R. Lloyd,&nbsp;Ricardo Franco,&nbsp;Martin F. Shapiro,&nbsp;Elaine Wethington","doi":"10.1111/jvh.70093","DOIUrl":"https://doi.org/10.1111/jvh.70093","url":null,"abstract":"<div>\u0000 \u0000 <p>Objective:To identify specialty-specific influences in administering HCV treatment among primary care, gastroenterology/hepatology, infectious diseases, and addiction specialties, and strategies to potentially eliminate HCV. Study Setting and Design:Qualitative study using remote interviews with healthcare providers in New York and Alabama who treated or screened patients for HCV, purposefully sampling for specialty, clinical setting, and HCV treatment experience. Data sources and Analytic Sample: Interviews occurred 9/2021–8/2022. Transcripts were analyzed using a hybrid inductive-deductive approach; a content analysis identified codes arising uniquely within specialties. Results: Thirty-six providers were interviewed: primary care (<i>n</i> = 9), addiction medicine (<i>n</i> = 12), infectious diseases (<i>n</i> = 9), and gastroenterology/hepatology (<i>n</i> = 6). Distinct challenges and facilitators emerged across specialties. Primary care and addiction providers similarly emphasized the convenience and usual practice of referring patients to specialists for HCV treatment, while infectious disease and gastroenterology noted challenges with patients not completing the referrals. Primary care providers expressed wanting training and peer support related to treatment provision. Addiction providers described structural barriers, such as lacking on-site phlebotomy services and patients' competing health concern prioritization, but highlighted strategies to improve treatment access, including trust-building. Infectious disease providers highlighted using patient navigators to overcome logistical barriers, while gastroenterologists emphasized collaborative relationships, particularly with addiction specialists. Specialty-specific opportunities emerged regarding training, collaboration, navigation, and infrastructure. Conclusions:Eliminating HCV requires addressing specialty-specific concerns for providers managing HCV. Potential opportunities include dissemination of specialty-tailored training, facilitating interdisciplinary care and desired cross-specialty collaborations, and overcoming unique infrastructural needs. Future research should evaluate implementation strategies addressing these specialty-specific needs.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam","authors":"Didier Laureillard,&nbsp;Nguyen Thanh Binh,&nbsp;Vu Hai Vinh,&nbsp;Tran Thi Hong,&nbsp;Catherine Quillet,&nbsp;Nham Thi Tuyet Thanh,&nbsp;Roselyne Vallo,&nbsp;Bach Thi Nhu Quynh,&nbsp;Jean Pierre Moles,&nbsp;Khuat Thi Hai Oanh,&nbsp;Duong Thi Huong,&nbsp;Delphine Rapoud,&nbsp;Jonathan Feelemyer,&nbsp;Laurent Michel,&nbsp;Peter Vickerman,&nbsp;Hannah Fraser,&nbsp;Laurence Weiss,&nbsp;Maud Lemoine,&nbsp;Karine Lacombe,&nbsp;Don Des Jarlais,&nbsp;Pham Minh Khue,&nbsp;Nicolas Nagot","doi":"10.1111/jvh.70090","DOIUrl":"10.1111/jvh.70090","url":null,"abstract":"<p>People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low- and middle-income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high-risk population. Here, we report the safety and efficacy of a pangenotypic generic HCV treatment among PWID in Vietnam, using a sofosbuvir/daclatasvir regimen. PWID were screened for HCV at two community-based organisations (CBO) premises in Haiphong during both a respondent-driven sampling survey and cohort follow-up visits. PWID with detectable HCV RNA were referred to three public hospitals for a 12-week regimen of generic sofosbuvir/daclatasvir, with ribavirin if cirrhosis, and with CBO support for referral and adherence. Treatment safety was assessed over the course of treatment and success was measured by sustained virologic response 12 weeks after the end of treatment (SVR12). Of the 1201 PWID screened with detectable HCV RNA, 1021 were enrolled: 96% male, median age 42 years, 45% HIV-infected, 16% with advanced liver fibrosis, 55% currently injecting, and 71.5% on methadone maintenance therapy (MMT). In total, 979 participants started HCV treatment, and 901 of the 924 participants tested at SVR12 (98%) were cured. Genotype 3, current drug use, lack of MMT, and HIV infection were independently associated with treatment failure. High HCV cure rates can be achieved among PWID in LMICs such as Vietnam using a simple model of care, including a pangenotypic generic direct-acting antiviral combination and CBO support.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT03537196</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HCV Testing and Treatment of Adults in the United States: 2014 Through 2021—Data From Two National Commercial Testing Laboratories","authors":"Marc G. Ghany,&nbsp;John W. Ward,&nbsp;Zachary Baldwin,&nbsp;Shiyin Jiao,&nbsp;Nidhi Shukla,&nbsp;Arina Kuznetsova,&nbsp;Jatinder Kaur,&nbsp;Katherine J. Kosch,&nbsp;Timothy R. Morgan","doi":"10.1111/jvh.70087","DOIUrl":"10.1111/jvh.70087","url":null,"abstract":"<p>Data on the hepatitis C virus (HCV) care cascade are crucial for determining if the United States (U.S.) is on track to meet 2016 World Health Organization elimination goals. De-identified data were analysed from persons who were screened for HCV antibody and/or tested for HCV RNA by two large U.S. commercial laboratories from 1/1/2014 to 12/31/2021. Validated imputation algorithms were used to identify persons who initiated treatment and who achieved virological cure based on viral load decline and continued negative HCV RNA test results. The 3-digit ZIP code was used to map treatment rates by U.S. state. During 1/1/2014 to 12/31/2021, a total of 46,646,661 persons were tested for HCV antibody of whom 2,253,500 (4.8%) were positive. Among 3,117,372 persons tested for HCV RNA, 1,951,742 (62.6%) were viremic. Cumulatively, a total of 672,745/1,951,742 (34.5%) viremic persons were treated; an estimated 643,043 (96%) were cured. Treatment rates increased with older age, higher fibrosis scores, HIV positivity, residing in an urban area and in the Northeast. Persons diagnosed by reflex testing had higher treatment rates. Comparing COVID-19 pandemic (2021) to pre-pandemic (2019) periods, 24% more HCV antibody tests were performed (10,167,524 vs. 7,727,318), but fewer persons were treated (21,136 vs. 26,124, 23% decline) and cured (19,584 vs. 24,480, 25.0% decline) in 2021, respectively. In 2021, primary care providers diagnosed and treated the greatest proportion of persons. Treatment uptake across the U.S. remains low, underscoring the need for additional measures to expand access to testing and treatment, necessary to reach the U.S. goals for HCV elimination by 2030.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Blood Droplet Volumes on the Cobas Plasma Separation Card for HCV RNA Testing in Resource-Limited Settings","authors":"Huma Qureshi,&nbsp;Jesse A. Canchola,&nbsp;Ghayas Hai,&nbsp;Amtul Quddos Latif,&nbsp;Neil T. Parkin,&nbsp;Benjamin La Brot","doi":"10.1111/jvh.70091","DOIUrl":"https://doi.org/10.1111/jvh.70091","url":null,"abstract":"<p>Detection of viral RNA is essential for hepatitis C virus (HCV) diagnosis. Collection and preservation of plasma, the preferred specimen type, is challenging in some areas. The Cobas Plasma Separation Card (PSC) is an alternative specimen type with no cold chain requirements. The PSC is designed to use capillary blood from fingerstick and capillary tube collection, but alternative sample collection options would broaden PSC utility. This study explored qualitative and quantitative HCV RNA detection with PSC prepared using a syringe needle, compared to plasma. Using a 24-gauge syringe, blood was drawn by venipuncture from HCV antibody-positive clinic patients aged &gt; 18 years and used to prepare plasma or spotted directly onto three PSCs using 6, 8 and 10 drops per spot (group 1) or 8, 10 and 12 drops (group 2). HCV RNA was measured using the Cobas HCV assay. Test results for all conditions were available for 143 patients in group 1 and 109 patients in group 2. The proportions with detectable HCV RNA were not significantly different from plasma, and overall agreement was over 88% for any PSC spot number (Fisher exact test <i>p</i> &gt; 0.1). The mean HCV viral load was lower for PSC samples vs. plasma for six or eight spots in group 1 but not statistically different for 10 or 12 spots in either group. Direct spotting of blood using a syringe is a viable alternative to finger prick and capillary tube transfer for PSC preparation. This approach may be beneficial in resource-limited settings and in patient populations for whom capillary blood collection is challenging.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linkage to Care, Retention in Care and Treatment Uptake Among Patients Diagnosed With Chronic Hepatitis B in Norway, 2008–2022","authors":"Beatriz Valcarcel Salamanca,&nbsp;Asgeir Johannessen,&nbsp;Olav Dalgard,&nbsp;Robert Whittaker","doi":"10.1111/jvh.70089","DOIUrl":"https://doi.org/10.1111/jvh.70089","url":null,"abstract":"<p>People living with chronic hepatitis B infection (PLWHB) need life-long care to monitor liver health and treatment need. Data on clinical follow-up for PLWHB are essential to monitor the health system response to this infection. We used linked national registry data to calculate the proportion of diagnosed PLWHB in Norway linked to specialist care (LTC), treated and retained in specialist or primary care (RIC) from 2008 to 2022. We described the outcomes by time, age, sex, region of residence, place of birth and residence status. Using log-binomial regression, we explored how these factors were associated with ever being LTC and being RIC during the last 12 months of the study period. Among 10,542 diagnosed PLWHB, 8301 (79%) had ever been LTC and 2454 (23%) had received treatment. In the first 2 years after LTC, 64% were still RIC. At the end of the study period, 4476 (50%) of 8979 PLWHB still resident in Norway had been RIC in the last 12 months. PLWHB born outside Norway had a higher probability of LTC (relative risk [RR]: 1.24; 95% confidence interval [CI] 1.19–1.29) and RIC (RR: 1.67; 95% CI 1.53–1.84). Other significant associations with smaller effect sizes included a higher probability of LTC among PLWHB aged &lt; 25 years and a lower probability of RIC when diagnosed from 2010 to 2013 or aged ≥ 65 years. The management of diagnosed PLWHB in Norway is suboptimal. Our study provides a framework for how key performance indicators can be monitored in ongoing national surveillance.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Profiles of Cytokines and Chemokines in Self-Limiting Hepatitis E","authors":"Pooja Bhatia,&nbsp;Aas Mohd,&nbsp;Harshita Katiyar,&nbsp;Amit Goel,&nbsp;Rakesh Aggarwal,&nbsp;Naga Suresh Veerapu","doi":"10.1111/jvh.70088","DOIUrl":"10.1111/jvh.70088","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis E virus infection typically results in a self-limited acute viral hepatitis (AVH-E), which is rapidly cleared by the host immune response. In this longitudinal study, temporal cytokine and chemokine profiles were analysed in AVH-E patients' sera using a multiplex immunoassay. HEV RNA became undetectable between 9 and 18 days, with a median of 13 days, occurring 3–20 days after symptom onset. In the AVH-E group, IFN-γ peaked significantly around days 6–9, which is prior to the HEV RNA clearance period, and declined during days 9–18. IL-2, IL-10, and TNF-α increased significantly during days 15–20, while IL-1β and IL-6 showed peak levels. CCL3, CXCL6, CXCL9, CXCL10 and MIF were significantly higher in the AVH-E group than in the healthy controls; CCL2 and CCL20 peaked non-significantly during days 12–17. CCL3, CXCL6, CXCL9 and CXCL10 levels were lower in the AVH-E group than in the AVH-B group. Compared to the AVH-B group and healthy controls, the AVH-E group showed distinct immune signatures. These findings highlight coordinated cytokine and chemokine responses during HEV infection and provide insights into the immunopathogenesis of self-limiting hepatitis E.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U-Shaped Relationship Between CT-Measured Liver-To-Spleen Volume Ratio and Mortality in HBV-ACLF Patients","authors":"Libo Yan,&nbsp;Man Yuan,&nbsp;Mao Su,&nbsp;Kunping Cui,&nbsp;Xiangnan Teng,&nbsp;Fang Yuan,&nbsp;Lang Bai","doi":"10.1111/jvh.70076","DOIUrl":"10.1111/jvh.70076","url":null,"abstract":"<p>Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a life-threatening condition with high short-term mortality, making early prognosis crucial. The liver-to-spleen volume ratio (LSVR) provides important prognostic information but is not included in current tools. This study evaluated the link between LSVR from computed tomography and short-term mortality in HBV-ACLF patients. The study included 278 patients, divided into five groups based on LSVR quintiles. The main outcome was 28-day mortality, with a secondary focus on 90-day mortality. Multivariable Cox regression and restricted cubic splines were used to analyse the LSVR-mortality relationship. Participants had a mean age of 48 years, 82.7% were male, with 28- and 90-day mortality rates of 23.4% and 31.3%, respectively. After adjusting for covariates, the risk of 28-day mortality was elevated by 553% (OR 6.53, 95% CI 1.86–23) in the highest quintile of LSVR (Q5 ≥ 3.6) and by 343% (OR 4.43, 95% CI 1.14–17.16) in the lowest quintile (Q1 ≤ 1.6), as compared to the reference quintile (Q3 2.4–2.9). The curve-fitting results showed a U-shaped relationship between LSVR and the risk of 28-day mortality and 90-day mortality, with an infection point of 2.7. There is a U-shaped relationship between LSVR and mortality in HBV-ACLF patients. Higher or lower LSVR is associated with an increased risk of short-term mortality in HBV-ACLF patients.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Factors Associated With Hepatitis B Virus Infection in Tigray Region, Northern Ethiopia","authors":"Gessessew Bugssa,&nbsp;Tilahun Teklehaymanot,&nbsp;Girmay Medhin,&nbsp;Shevanti Nayagam,&nbsp;Asgeir Johannessen,&nbsp;Nega Berhe","doi":"10.1111/jvh.70077","DOIUrl":"https://doi.org/10.1111/jvh.70077","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis B virus (HBV) infection is a significant public health concern, particularly in low-income countries. This study investigates the prevalence and associated risk factors of HBV in Alamata district of Tigray region, northern Ethiopia, where the HBV vaccine was introduced in the childhood vaccination programme in 2007. A community-based, cross-sectional study was conducted from December 2019 to June 2020. Data were collected using structured questionnaires and hepatitis B surface antigen (HBsAg) was measured using a rapid diagnostic test. Logistic regression analyses were used to determine the associations between socio-demographic, behavioural and health-related variables and HBV infection. A total of 1853 individuals (54.2% females) were included in this study. The age ranged from 5 to 88 years, and the largest age group was from 5 to 14 years (32.0%). The overall HBV prevalence was 5.3% (95% confidence interval (CI) 4.3–6.3) with significant variability between age groups: 5–14 years 3.7%, 15–24 years 6.8%, 25–34 years 10.1%, 35–44 years 4.4%, 45–54 years 3.9% and 55 years and above 3.4%. Being in the 25–34 years age group (adjusted odds ratio (AOR) 4.1, 95% CI: 1.1–16.2, P= 0.042), reporting multiple sexual partners (AOR 4.0, 95% CI: 1.02–15.4, P= 0.047) and family history of hepatitis B (AOR 3.1, 95% CI: 1.2–8.2, P= 0.024) were independently associated with HBV infection. The prevalence of HBV infection was high in this region, underscoring the necessity for targeted public health strategies aimed at reducing transmission rates. Of note, the HBV prevalence was significantly lower among children born after the introduction of the HBV vaccine.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer-Delivered Outreach With Rapid Treatment Pathways for Hepatitis C Testing and Treatment Among Unhoused People","authors":"Gabriele Vojt,&nbsp;Philippe Bonnet,&nbsp;Jennifer Scott,&nbsp;Emma Hathorn,&nbsp;Lisa Ellis,&nbsp;Sally Bufton,&nbsp;David Mutimer,&nbsp;Ryan Buchanan,&nbsp;Leila Reid,&nbsp;Danny Morris,&nbsp;Ahmed Elsharkawy","doi":"10.1111/jvh.70085","DOIUrl":"https://doi.org/10.1111/jvh.70085","url":null,"abstract":"<p>This service evaluation describes the co-development of a peer-led rapid hepatitis C virus (HCV) pathway to reach unhoused people. A trained and qualified peer worker visited homeless shelters in West Midlands, England, setting up test and treatment events and collaborating with local services and healthcare staff who also attended the sites. The peer worker offered point of care HCV antibody and ribonucleic acid (RNA) testing for individuals at risk of HCV, peer education and support before and during treatment. Viraemic individuals were offered immediate treatment prescribed by local HCV clinical specialist nurses who attended the homeless shelters with the peer worker. Among the 140 tested individuals, 72 people (51.4%) were HCV antibody positive and 42 (30.0%) were HCV RNA positive. All participants had a history of injecting drug use. The majority were male (75.0%), with a mean age of 39 years and of white ethnicity (89.4%). Treatment uptake was 100.0%, and known treatment completion was 92.3%. Treatment uptake within 2 weeks was 57.1%. Findings suggest that the co-developed and peer-led HCV test and treat pathway is promising in case finding, testing and treating marginalised, unhoused people.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Adherence Trajectories in Chronic Hepatitis B: A Cluster-Based Approach to Long-Term Treatment Management","authors":"Lin Zhang,&nbsp;Huichun Ji,&nbsp;Suhua Pang,&nbsp;Youde Yan,&nbsp;Zhenjiang Zhang","doi":"10.1111/jvh.70068","DOIUrl":"https://doi.org/10.1111/jvh.70068","url":null,"abstract":"<div>\u0000 \u0000 <p>This study aimed to investigate the levels and longitudinal trajectories of medication adherence among patients with chronic hepatitis B (CHB), identify key psychosocial factors influencing adherence and provide evidence to inform strategies for optimising long-term treatment and enhancing patients' quality of life. A longitudinal study was conducted among CHB patients, 305 completing a 12-month follow-up. Medication adherence and psychosocial data were collected at baseline and at 3, 6, 9 and 12 months. <i>K</i>-means cluster analysis was performed to identify distinct adherence patterns, and differences in psychosocial characteristics across clusters were analysed. Four adherence trajectories were identified: improvement, low adherence, decline and high adherence. Significant differences were observed among the groups in terms of medication adherence scores and psychosocial factors (<i>p</i> &lt; 0.05). Higher adherence was positively correlated with self-efficacy and social support, while lower adherence was associated with higher levels of perceived stigma and depression. Medication adherence among CHB patients exhibits distinct dynamic patterns, strongly influenced by psychosocial factors. Targeted interventions focusing on psychological support, stigma reduction and strengthening social support networks may improve adherence and ultimately enhance the quality of life for patients with chronic hepatitis B.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}